Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical implications of ctDNA for EGFR-TKIs as first-line treatment in NSCLC.

Journal of cancer research and clinical oncology - 1 Mar 2023

Liang Xiao, Zhang Wei, Li Jun, Zhu Jing, Shao Jun, Wang Jing, Wu Hongshuai, Dai Jiali, Li Jun, Xu Jiali, Wang Wei, Guo Renhua

Abstract excerpt

PURPOSE: This study aimed to explore the clinical implications of ctDNA for epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) as the first-line treatment in EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC) in real-world settings. METHODS: A total of 122 patients with NSCLC who underwent tissue and liquid next generation sequencing (NGS) tests were included. 66 patients with detected...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to DNA

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Mutation

Share to Prognosis

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 35380256
DOI: 10.1007/s00432-022-03952-z

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical implications of ctDNA for EGFR-TKIs as first-line treatment in NSCLC.PMID 35380256Read ↗

Real-world analysis of the prognostic value of EGFR mutation detection in plasma ctDNA from patients with advanced non-small cell lung cancer.Semantic proximity Read ↗

Plasma ctDNA increases tissue NGS-based detection of therapeutically targetable mutations in lung cancers.Semantic proximity Read ↗

Clinical utility of ctDNA by amplicon based next generation sequencing in first line non small cell lung cancer patients.Semantic proximity Read ↗

Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial.Semantic proximity Read ↗

Target-based genomic profiling of ctDNA from Chinese non-small cell lung cancer patients: a result of real-world data.Semantic proximity Read ↗

Circulating tumor DNA is effective for the detection of EGFR mutation in non-small cell lung cancer: a meta-analysis.Semantic proximity Read ↗

Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung Cancer.Semantic proximity Read ↗

EGFR T790M ctDNA testing platforms and their role as companion diagnostics: Correlation with clinical outcomes to EGFR-TKIs.Semantic proximity Read ↗

Disease monitoring of epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer patients treated with tyrosine kinase inhibitors via EGFR status in circulating tumor DNA.Semantic proximity Read ↗

Concordance of ctDNA and tissue mutations in NSCLC: A meta-analysis.Semantic proximity Read ↗

Clinical validity and utility of circulating tumor DNA (ctDNA) testing in advanced non-small cell lung cancer (aNSCLC): a systematic literature review and meta-analysisSemantic proximity Read ↗

Prognostic value of plasma EGFR ctDNA in NSCLC patients treated with EGFR-TKIs.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.